Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders

Details for Australian Patent Application No. 2009259026 (hide)

Owner AstraZeneca AB

Inventors Su, Mei; Ioannidis, Stephanos; Peng, Bo; Chuaqui, Claudio Edmundo; Almeida, Lynsie

Agent Davies Collison Cave

Pub. Number AU-B-2009259026

PCT Pub. Number WO2009/150462

Priority 61/060,784 11.06.08 US

Filing date 10 June 2009

Wipo publication date 17 December 2009

Acceptance publication date 4 October 2012

International Classifications

C07D 401/14 Heterocyclic compounds containing two or more hetero rings

A61K 31/53 - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61P 35/00 Antineoplastic agents

C07D 403/12 Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 403/14 Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 413/14 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 417/14 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

6 January 2011 PCT application entered the National Phase

  PCT publication WO2009/150462 Priority application(s): WO2009/150462

4 October 2012 Application Accepted

  Published as AU-B-2009259026

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009259033-Suppression of neuroendocrine diseases

2009259024-Genetic component of complications in type 2 diabetes